← Back to Clinical Trials
Recruiting NCT07491718

Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy

Trial Parameters

Condition Takotsubo Cardiomyopathy
Sponsor University of Edinburgh
Study Type INTERVENTIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-08-08
Completion 2028-08-09
Interventions
BisoprololValsartansacubitril/ valsartan

Brief Summary

The goal of this research study is to further understand the physiological mechanisms involved in a heart condition called takotsubo cardiomyopathy, also known as broken heart syndrome. Furthermore, the investigators will be assessing the effects different cardiac medications have on these physiological mechanisms. This will be achieved by performing cardiac MRI scans using a special dye called manganese. Manganese uptake in the heart is altered in patients with takotsubo cardiomyopathy. The investigators will study the effects that different cardiac medications have on manganese uptake.

Eligibility Criteria

Inclusion Criteria: * Males and females \>18 years of age * Clinical presentation of takotsubo cardiomyopathy * Have capacity to give formal consent Exclusion Criteria: * Unable to tolerate or contraindication to magnetic resonance imaging * Renal failure (estimated glomerular filtration rate \<30 mL/min/1.73 m2) - this would be assessed by performing a blood test * Prior history of cardiomyopathy * Current pregnancy * Weight greater than 250kg * Severe asthma for study 1 (given Bisoprolol is contraindicated in this condition) * Type 1 diabetes mellitus for study 2 (given Dapaglifozin is contraindicated in this population) * Significant hypotension (given the medications prescribed as part of the study can also cause hypotension as a side effect) * Significant bradycardia for study 1 (given Bisoprolol can exacerbate any pre-existing significant bradycardia) * Prescribed Digoxin (this medication interacts with the Manganese) * Unable to give formal consent

Related Trials